Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 12, 2012, Pages 1868-1875

  Boubaker, Ariane ^a   Prior, John O ^a   Willi, Jean Pierre ^b   Champendal, Melanie ^a   Kosinski, Marek ^a   Delaloye, Angelika Bischof ^a   Maecke, Helmut R ^c   Ginj, Mihaela ^d   Baechler, Sébastien ^a   Buchegger, Franz ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

111In DOTA NOC ATE; 111In DTPA octreotide; Biokinetics; Dosimetry; Neuroendocrine tumours; Somatostatin receptor

Indexed keywords

DOTA NOC ATE IN 111; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG; 111IN (1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID (DOTA(0)),1 NAL(3),THR(8))OCTREOTIDE; 111IN OCTREOTIDE, DTPA(0); 111IN-(1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID (DOTA(0)),1-NAL(3),THR(8))OCTREOTIDE; 111IN-OCTREOTIDE, DTPA(0)-; DIAGNOSTIC AGENT; DRUG DERIVATIVE; OCTREOTIDE; ORGANOMETALLIC COMPOUND; PENTETIC ACID;

ARTICLE; BINDING AFFINITY; BLOOD ANALYSIS; BLOOD CELL; BRAIN SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG HALF LIFE; FEMALE; HUMAN; MALE; NEUROENDOCRINE TUMOR; PLASMA; THYMOMA; THYROID MEDULLARY CARCINOMA; THYROID SCINTISCANNING; ADULT; AGED; COMPARATIVE STUDY; MIDDLE AGED; RADIOMETRY; SCINTISCANNING; THYROID TUMOR; TISSUE DISTRIBUTION;

ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PENTETIC ACID; RADIOMETRY; RADIOPHARMACEUTICALS; THYMOMA; THYMUS NEOPLASMS; THYROID NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84869095115     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2210-0     Document Type: Article

References (11)

1. Reubi JC, Perrin MH, Rivier JE, Vale W. High affinity binding sites for a somatostatin-28 analog in rat brain. Life Sci. 1981;28:2191-8. (Pubitemid 11089615)
2. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157-98. (Pubitemid 29362641)
3. Ginj M, Chen J, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogs of octreotide for targeted radiotherapy. Eur J Nucl Med Mol Imaging. 2003;30:S198-9.
4. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med. 2001;28:836-46. (Pubitemid 32662546)
5. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res. 2005;11:1136-45. (Pubitemid 40175763)
6. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The secondgeneration personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-7. (Pubitemid 43733519)
7. Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med. 2004;45:1725-33. (Pubitemid 47618483)
8. Meyer SL. Data analysis for scientists and engineers. New York: Wiley; 1975. ISBN: 0-471-59995-6.
9. ICRP. Radiation dose to patients from radiopharmaceuticals - Addendum 3 to ICRP publication 53. ICRP publication 106. Ann ICRP. 38 (1-2)
10. Stabin MG, Kooij PP, Bakker WH, Inoue T, Endo K, Coveney J, et al. Radiation dosimetry for indium-111-pentetreotide. J Nucl Med. 1997;38:1919-22. (Pubitemid 28030923)
11. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72-9. (Pubitemid 350234154)